Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study.
Ito H, Tsugami E, Ando S, Araki R, Matsumoto S, Uemura K, Nishio S, Antoku S, Yamasaki T, Mori T, Togane M. Ito H, et al. Among authors: mori t. J Drug Assess. 2018 Sep 5;7(1):54-60. doi: 10.1080/21556660.2018.1513846. eCollection 2018. J Drug Assess. 2018. PMID: 30202634 Free PMC article.
Changes in medication adherence and unused drugs after switching from daily dipeptidyl peptidase-4 inhibitors to once-weekly trelagliptin in patients with type 2 diabetes.
Ito H, Ando S, Tsugami E, Araki R, Kusano E, Matsumoto S, Uemura K, Nishio S, Antoku S, Yamasaki T, Mori T, Togane M. Ito H, et al. Among authors: mori t. Diabetes Res Clin Pract. 2019 Jul;153:41-48. doi: 10.1016/j.diabres.2019.05.025. Epub 2019 May 28. Diabetes Res Clin Pract. 2019. PMID: 31150724
Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes.
Ito H, Matsumoto S, Izutsu T, Kusano E, Nishio S, Antoku S, Yamasaki T, Mori T, Togane M, Ando S, Tsugami E. Ito H, et al. Among authors: mori t. Diabetes Metab Syndr Obes. 2019 Sep 9;12:1783-1794. doi: 10.2147/DMSO.S221655. eCollection 2019. Diabetes Metab Syndr Obes. 2019. PMID: 31571954 Free PMC article.
Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation.
Ito H, Matsumoto S, Izutsu T, Kusano E, Kondo J, Inoue H, Antoku S, Yamasaki T, Mori T, Togane M. Ito H, et al. Among authors: mori t. PLoS One. 2021 Mar 15;16(3):e0248577. doi: 10.1371/journal.pone.0248577. eCollection 2021. PLoS One. 2021. PMID: 33720983 Free PMC article. Clinical Trial.
Erratum for Early Improvement of Non-islet Cell Tumor Hypoglycemia by Chemotherapy Using Lenvatinib in a Case with Type 2 Diabetes and Hepatocellular Carcinoma Producing Big IGF-II.
Izutsu T, Ito H, Fukuda I, Tamura H, Matsumoto S, Antoku S, Mori T, Goto H. Izutsu T, et al. Among authors: mori t. Intern Med. 2021;60(12):1985. doi: 10.2169/internalmedicine.E003-21. Epub 2021 Jun 15. Intern Med. 2021. PMID: 34135269 Free PMC article. No abstract available.
9,301 results